- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vericel Corp Ord (VCEL)Vericel Corp Ord stock price live, this page displays NASDAQ VCEL stock exchange data. View the VCEL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vericel Corp Ord real time stock price chart below.
What Is the Vericel Corp Ord Stock Price Today?
The Vericel Corp Ord stock price today is 58.15.
What Is the Stock Symbol for Vericel Corp Ord?
The stock ticker symbol for Vericel Corp Ord is VCEL.
Is VCEL the Same as $VCEL?
$VCEL is a common way to refer to the Vericel Corp Ord ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Vericel Corp Ord Trade On?
Vericel Corp Ord is listed and trades on the NASDAQ stock exchange.
Is Vericel Corp Ord a Good Stock to Buy?
Determining whether Vericel Corp Ord—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Vericel Corp Ord share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VCEL quote. (ISIN: US92346J1088)
What Is the Vericel Corp Ord Stock Price Today?
The Vericel Corp Ord stock price today is 58.15.
What Is the Stock Symbol for Vericel Corp Ord?
The stock ticker symbol for Vericel Corp Ord is VCEL.
Is VCEL the Same as $VCEL?
$VCEL is a common way to refer to the Vericel Corp Ord ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Vericel Corp Ord Trade On?
Vericel Corp Ord is listed and trades on the NASDAQ stock exchange.
Is Vericel Corp Ord a Good Stock to Buy?
Determining whether Vericel Corp Ord—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Vericel Corp Ord share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VCEL quote. (ISIN: US92346J1088)
58.15
-0.09(-0.15%)
Closed
After Hours
61.25+3.10(+5.33%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
57.03
59.85
52 wk Range
32.31
61.49
VCEL Scorecard
Full Analysis
Net income is expected to grow this year
Unusual Post-Market activity
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
57.0359.85
52 wk Range
32.3161.49
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockVCEL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
61.50
Upside
+5.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
- Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - VCEL stock soars to 52-week high, reaching $54.12
- Investing.com
Vericel Corp Ord Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel Corp Ord SWOT Analysis
Financial Outlook | Analysts project potential doubling of MACI revenues, with Canaccord Genuity setting a $57 price target. Explore the balance of growth potential and expansion costs |
Competitive Edge | Learn how MACI Arthro's unique approval pathway and arthroscopic application method strengthen Vericel's position in the cartilage repair market |
Market Expansion Strategy | Delve into Vericel's plans to tap into a $3 billion addressable market, targeting high-volume surgeons and expanding its sales force for MACI Arthro's success |
MACI Arthro Breakthrough | Explore Vericel's game-changing FDA approval for MACI Arthro, the only arthroscopic biologic cartilage repair product in the U.S., expanding its market reach |
VCEL Full Pro Research
Institutional-Grade Stock Analysis
Understand how VCEL earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Vericel Corp Ord Earnings Call Summary for Q3/2024
- Vericel reported record Q2 revenue of $53M, driven by MACI growth and NexoBrid demand; reaffirmed 20%+ annual revenue growth guidance
- Gross margin improved by 400+ basis points; adjusted EBITDA grew 42% YoY; company raised profitability outlook for the year
- MACI Arthro launch and expected NexoBrid pediatric approval anticipated to drive future growth; Q3 revenue forecast at $55M
- Company expects to be GAAP profitable for full year 2024, with continued high revenue and profit growth projected beyond
- Strategic focus on innovation and financial performance, with MACI gaining acceptance as standard-of-care for cartilage repair
Last Updated: 08/04/2024, 01:43 PM
Read Full TranscriptCompare VCEL to Peers and Sector
Metrics to compare | VCEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVCELPeersSector | |
|---|---|---|---|---|
P/E Ratio | 809.0x | −1.3x | −0.7x | |
PEG Ratio | 6.05 | 0.00 | 0.00 | |
Price / Book | 11.1x | 2.2x | 2.6x | |
Price / LTM Sales | 12.7x | 9.9x | 3.2x | |
Upside (Analyst Target) | 3.9% | 90.8% | 45.9% | |
Fair Value Upside | Unlock | 4.2% | 7.6% | Unlock |
Analysts' Recommendations
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 61.50
(+5.76% Upside)
People Also Watch
FAQ
What Is the Vericel Corp Ord (VCEL) Stock Price Today?
The Vericel Corp Ord stock price today is 58.15
What Stock Exchange Does Vericel Corp Ord Trade On?
Vericel Corp Ord is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Vericel Corp Ord?
The stock symbol for Vericel Corp Ord is "VCEL."
What Is the Vericel Corp Ord Market Cap?
As of today, Vericel Corp Ord market cap is 2.87B.
What is Vericel Corp Ord Earnings Per Share?
The Vericel Corp Ord EPS is 0.073.
What Is the Next Vericel Corp Ord Earnings Date?
Vericel Corp Ord will release its next earnings report on Mar 04, 2025.
From a Technical Analysis Perspective, Is VCEL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.